Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2026)

Beam Therapeutics (BEAM) has reported Free Cash Flow for 8 consecutive years, with -$130.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 22.25% year-over-year to -$130.7 million; the TTM figure through Mar 2026 stood at -$370.2 million (down 4.91% YoY), while the FY2025 annual figure was -$346.4 million, changed 0.49% from the prior year.
• Free Cash Flow slipped to -$130.7 million in Q1 2026 per BEAM's latest filing, from -$81.4 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $203.2 million in Q1 2022 and bottomed at -$130.7 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$59.0 million across 5 years, with a median of -$84.2 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 624.17% in 2022 and fell as far as 3733.5% in 2022.
• Beam Therapeutics' Free Cash Flow stood at -$77.5 million in 2022, then soared by 311.5% to $163.8 million in 2023, then plunged by 146.85% to -$76.7 million in 2024, then dropped by 6.11% to -$81.4 million in 2025, then plunged by 60.55% to -$130.7 million in 2026.
• Business Quant data shows BEAM's Free Cash Flow at -$130.7 million in Q1 2026, -$81.4 million in Q4 2025, and -$78.4 million in Q3 2025.